BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18055114)

  • 1. Local administration of a cannabinoid agonist alters norepinephrine efflux in the rat frontal cortex.
    Page ME; Oropeza VC; Van Bockstaele EJ
    Neurosci Lett; 2008 Jan; 431(1):1-5. PubMed ID: 18055114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic administration of WIN 55,212-2 increases norepinephrine release in the rat frontal cortex.
    Oropeza VC; Page ME; Van Bockstaele EJ
    Brain Res; 2005 Jun; 1046(1-2):45-54. PubMed ID: 15927549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabinoid receptors are localized to noradrenergic axon terminals in the rat frontal cortex.
    Oropeza VC; Mackie K; Van Bockstaele EJ
    Brain Res; 2007 Jan; 1127(1):36-44. PubMed ID: 17113043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A.
    Gessa GL; Casu MA; Carta G; Mascia MS
    Eur J Pharmacol; 1998 Aug; 355(2-3):119-24. PubMed ID: 9760025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeated cannabinoid administration increases indices of noradrenergic activity in rats.
    Page ME; Oropeza VC; Sparks SE; Qian Y; Menko AS; Van Bockstaele EJ
    Pharmacol Biochem Behav; 2007 Jan; 86(1):162-8. PubMed ID: 17275893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in guinea-pig vessels, but not in rat and mouse aorta.
    Schultheiss T; Flau K; Kathmann M; Göthert M; Schlicker E
    Naunyn Schmiedebergs Arch Pharmacol; 2005 Aug; 372(2):139-46. PubMed ID: 16195872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: an in vivo and in vitro study.
    Ferraro L; Tomasini MC; Gessa GL; Bebe BW; Tanganelli S; Antonelli T
    Cereb Cortex; 2001 Aug; 11(8):728-33. PubMed ID: 11459762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic, but not local, administration of cannabinoid CB1 receptor agonists modulate prefrontal cortical acetylcholine efflux in the rat.
    Verrico CD; Jentsch JD; Dazzi L; Roth RH
    Synapse; 2003 Jun; 48(4):178-83. PubMed ID: 12687636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons.
    Huang CC; Lo SW; Hsu KS
    J Physiol; 2001 May; 532(Pt 3):731-48. PubMed ID: 11313442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CB-1 receptors modulate the effect of the selective serotonin reuptake inhibitor, citalopram on extracellular serotonin levels in the rat prefrontal cortex.
    Kleijn J; Cremers TI; Hofland CM; Westerink BH
    Neurosci Res; 2011 Jul; 70(3):334-7. PubMed ID: 21420449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
    McMahon LR
    Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic effect of cannabinoids on the spontaneous firing rate of locus coeruleus neurons in rats.
    Mendiguren A; Pineda J
    Eur J Pharmacol; 2006 Mar; 534(1-3):83-8. PubMed ID: 16483566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
    McMahon LR; Koek W
    Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain.
    Kathmann M; Bauer U; Schlicker E; Göthert M
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Jun; 359(6):466-70. PubMed ID: 10431757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonism between the anti-inflammatory activity of the cannabinoid WIN 55212-2 and SR 141716A.
    Pozzi O; Misiano P; Clark GD; Visentin L
    Pharmacology; 2003 Nov; 69(3):158-63. PubMed ID: 14512703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats.
    Fattore L; Cossu G; Martellotta CM; Fratta W
    Psychopharmacology (Berl); 2001 Aug; 156(4):410-6. PubMed ID: 11498718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoid modulation of cortical adrenergic receptors and transporters.
    Reyes BA; Rosario JC; Piana PM; Van Bockstaele EJ
    J Neurosci Res; 2009 Dec; 87(16):3671-8. PubMed ID: 19533736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CB1 cannabinoid receptor stimulation during adolescence impairs the maturation of GABA function in the adult rat prefrontal cortex.
    Cass DK; Flores-Barrera E; Thomases DR; Vital WF; Caballero A; Tseng KY
    Mol Psychiatry; 2014 May; 19(5):536-43. PubMed ID: 24589887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity.
    Pan X; Ikeda SR; Lewis DL
    Mol Pharmacol; 1998 Dec; 54(6):1064-72. PubMed ID: 9855635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects on cortical glutamate release induced by prenatal exposure to the cannabinoid receptor agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinyl-methyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone: an in vivo microdialysis study in the awake rat.
    Antonelli T; Tanganelli S; Tomasini MC; Finetti S; Trabace L; Steardo L; Sabino V; Carratu MR; Cuomo V; Ferraro L
    Neuroscience; 2004; 124(2):367-75. PubMed ID: 14980386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.